Government of Kyrgyzstan Report issue

Government Phase 2 Phase 3 Phase 4
Founded: Bishkek Kyrgyzstan (1992)

Organization Overview

First Clinical Trial
2009
NCT00960921
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Ministry of Health, Kyrgyzstan | National Center of Cardiology and Internal Medicine, Bishkek, Kyrgyzstan | National Center of Cardiology and Internal Medicine, Kyrgyz Republic | National Center of Cardiology and Internal Medicine, Kyrgyzstan | National Center of Phthisiatry, Bishkek, Kyrgyzstan

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Altitude Sickness (Phase 4)

Bacterial Infections (Phase 3)

Hypertension (Phase 2)

Hypertension, Pulmonary (Phase 2)

Hypoxia (Phase 4)

Lung Diseases (Phase 4)

Lung Diseases, Obstructive (Phase 4)

Pulmonary Disease, Chronic Obstructive (Phase 4)

Respiration Disorders (Phase 4)

Respiratory Aspiration (Phase 4)

Respiratory Tract Diseases (Phase 4)

Sleep Apnea Syndromes (Phase 4)

Tuberculosis (Phase 3)

Tuberculosis, Multidrug-Resistant (Phase 3)

Tuberculosis, Pulmonary (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 24
  • # of Trial APIs: 13